These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 14508385)

  • 81. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 82. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability.
    Pirsch J; Bekersky I; Vincenti F; Boswell G; Woodle ES; Alak A; Kruelle M; Fass N; Facklam D; Mekki Q
    J Clin Pharmacol; 2000 May; 40(5):527-32. PubMed ID: 10806606
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
    Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.
    Kobayashi M; Saitoh H; Kobayashi M; Tadano K; Takahashi Y; Hirano T
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1029-35. PubMed ID: 14978191
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients.
    Cattaneo D; Gaspari F; Ferrari S; Stucchi N; Del Priore L; Perico N; Gotti E; Remuzzi G
    Clin Transplant; 2001 Dec; 15(6):402-9. PubMed ID: 11737117
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy.
    Tsaroucha AK; Zucker K; Esquenazi V; de Faria L; Miller J; Tzakis AG
    Transpl Immunol; 2000 Jun; 8(2):143-6. PubMed ID: 11005321
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function.
    Shaw LM; Mick R; Nowak I; Korecka M; Brayman KL
    J Clin Pharmacol; 1998 Mar; 38(3):268-75. PubMed ID: 9549665
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters.
    Figurski MJ; Pawiński T; Goldberg LR; DeNofrio D; Nawrocki A; Taylor DO; Lake KD; Chojnowski D; Shaw LM
    Ann Transplant; 2012; 17(1):68-78. PubMed ID: 22466911
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients.
    Woillard JB; Saint-Marcoux F; Monchaud C; Youdarène R; Pouche L; Marquet P
    Pharmacol Res; 2015 Sep; 99():308-15. PubMed ID: 26192348
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Shaw LM; Mathot RA
    Clin Pharmacokinet; 2009; 48(7):463-76. PubMed ID: 19691368
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus.
    Zhang HX; Sheng CC; Liu LS; Luo B; Fu Q; Zhao Q; Li J; Liu YF; Deng RH; Jiao Z; Wang CX
    Br J Clin Pharmacol; 2019 Apr; 85(4):746-761. PubMed ID: 30597603
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.
    Heller T; van Gelder T; Budde K; de Fijter JW; Kuypers D; Arns W; Schmidt J; Rostaing L; Powis SH; Claesson K; Macphee IA; Pohanka E; Engelmayer J; Brandhorst G; Oellerich M; Armstrong VW
    Am J Transplant; 2007 Jul; 7(7):1822-31. PubMed ID: 17532750
    [TBL] [Abstract][Full Text] [Related]  

  • 100. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients.
    Kagaya H; Miura M; Satoh S; Inoue K; Saito M; Inoue T; Habuchi T; Suzuki T
    J Clin Pharm Ther; 2008 Apr; 33(2):193-201. PubMed ID: 18315786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.